# Dermatology Times

> Dermatology Times - Healthcare Publication

- Base URL: https://www.dermatologytimes.com
- Generated: 2026-10-09T09:57:11.134Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.dermatologytimes.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.dermatologytimes.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.dermatologytimes.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.dermatologytimes.com/robots.txt](https://www.dermatologytimes.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [Aclinical Dermatitis](https://www.dermatologytimes.com/aclinical dermatitis)
- [Around the Practice](https://www.dermatologytimes.com/around-the-practice)
- [Between The Lines](https://www.dermatologytimes.com/between-the-lines)
- [Case-Based Peer Perspective](https://www.dermatologytimes.com/case-based-peer-perspective)
- [Clinical](https://www.dermatologytimes.com/clinical)
- [Clinical Case Collective](https://www.dermatologytimes.com/clinical-case-collective)
- [Clinical Role](https://www.dermatologytimes.com/clinical-role)
- [Conferences](https://www.dermatologytimes.com/conferences)
- [Conferences (Dont Use)](https://www.dermatologytimes.com/conference)
- [DermView](https://www.dermatologytimes.com/dermview)
- [Inside the Clinic](https://www.dermatologytimes.com/inside-the-clinic)
- [NO ADS](https://www.dermatologytimes.com/no-ads)
- [News](https://www.dermatologytimes.com/news)
- [Patient Perspectives](https://www.dermatologytimes.com/patient-perspectives)
- [Podcasts](https://www.dermatologytimes.com/podcasts)
- [Recognize and Refer](https://www.dermatologytimes.com/recognize-and-refer)
- [Resources](https://www.dermatologytimes.com/resources)
- [Role](https://www.dermatologytimes.com/role)
- [Video Series](https://www.dermatologytimes.com/video-series)
- [Viewpoints](https://www.dermatologytimes.com/viewpoints)

## Featured Content

- [Augmented Intelligence in Skin Cancer Detection and Prognosis](https://www.dermatologytimes.com/view/augmented-intelligence-in-skin-cancer-detection-and-prognosis): Shannon Trotter, DO, discusses augmented intelligence in skin cancer detection, the approval of remibrutinib for symptomatic dermatographism, and her...
- [Upadacitinib Shows Broader Inflammatory Effects and Earlier Skin Barrier Restoration Than Dupilumab in Atopic Dermatitis](https://www.dermatologytimes.com/view/upadacitinib-shows-broader-inflammatory-effects-and-earlier-skin-barrier-restoration-than-dupilumab-in-atopic-dermatitis): Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
- [Biofrontera Submits sNDA to Expand Ameluz PDT for Actinic Keratoses Across the Body](https://www.dermatologytimes.com/view/biofrontera-submits-snda-to-expand-ameluz-pdt-for-actinic-keratoses-across-the-body): The supplemental New Drug Application seeks to expand the use of Ameluz with red light photodynamic therapy beyond the face and scalp to actinic kerat...
- [Previewing the 2026 Fall Clinical Dermatology Conference](https://www.dermatologytimes.com/view/previewing-the-2026-fall-clinical-dermatology-conference): The 4-day CME meeting in Las Vegas offers up to 24.25 credits and sessions on inflammatory skin disease, skin cancer, pediatric dermatology, aesthetic...
- [Personalized Prescription Skin Care: Curology’s Whitney Tolpinrud, MD, on the Evolution of Virtual Dermatology](https://www.dermatologytimes.com/view/personalized-prescription-skin-care-curology-s-whitney-tolpinrud-md-on-the-evolution-of-virtual-dermatology): Whitney Tolpinrud, MD, discusses the evolution of personalized prescription skin care, patient expectations in the digital age, and clinical trends.
- [Where Patients Live Shapes Atopic Dermatitis Care Access, NEA Report Finds](https://www.dermatologytimes.com/view/where-patients-live-shapes-atopic-dermatitis-care-access-nea-report-finds): Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), reviews how state-level data from the NEA's State of AD 2026 National Indicator Re...
- [Abrocitinib Reduces Pathogenic Skin-Resident Memory T Cells in Atopic Dermatitis](https://www.dermatologytimes.com/view/abrocitinib-reduces-pathogenic-skin-resident-memory-t-cells-in-atopic-dermatitis): A biopsy-based analysis from the JADE MOA trial presented at EADV 2026 found reductions in pathogenic skin-resident memory T cells alongside restorati...
- [FDA Approves Remibrutinib for Symptomatic Dermographism](https://www.dermatologytimes.com/view/fda-approves-remibrutinib-for-symptomatic-dermographism): The approval of the oral BTKi rests on a phase 3 result of 29.3% complete response from hives vs 14.0% with placebo at week 12.
- [Journal Digest: October 7, 2026](https://www.dermatologytimes.com/view/journal-digest-october-7-2026): This week’s review highlights pediatric oral minoxidil guidance, alopecia areata imaging, inherited skin disorder growth patterns, total-body photogra...
- [Differentiating the Two Approved Hedgehog Inhibitors in BCC](https://www.dermatologytimes.com/view/differentiating-the-two-approved-hedgehog-inhibitors-in-bcc): Distinct pharmacokinetic profiles, including volume of distribution, half-life, and time to steady state, differentiate the two approved hedgehog inhi...

## Feeds and Indexes

- [RSS Feed](https://www.dermatologytimes.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.dermatologytimes.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.dermatologytimes.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.dermatologytimes.com/authors): Browse all contributors and their published work